PIK3CA and breast carcinoma: Therascreen PIK3CA RGQ PCR kit, another PCR-based assay, was approved for the assessment of PIK3CA mutations in plasmatic cfDNA collected from patients affected by advanced hormone receptor-positive HER2-negative breast cancer.